Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 6/2004

01.12.2004 | Review

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens

verfasst von: Anthony Howell, Mitch Dowsett

Erschienen in: Breast Cancer Research | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

Endocrine therapies act by either blocking or downregulating the oestrogen receptor or by reducing oestrogen concentrations around and within the cancer cell. In postmenopausal women, oestrogen suppression is achieved by inhibition of the enzyme aromatase by aromatase inhibitors (AIs). Modern AIs (anastrozole, letrozole and exemestane) are more potent than earlier ones and suppress oestradiol levels in plasma to virtually undetectable concentrations. Recent comparisons of AIs with the most widely used oestrogen receptor blocking drug tamoxifen indicate that, in general, AIs result in increased response rates and greater durations of response. Here, we summarize data supporting the difference between the two types of treatment and attempt to account for the underlying mechanisms that favour AIs.
Literatur
1.
Smith IE, Harris AL, Morgan M, Gazet JC, McKinna JA: Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 1982, Suppl: 3430s-3433s.
2.
Gale KE, Anderson JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, Cummings FJ: Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer. 1994, 12: 1630-1638.
3.
Perez Carrion R, Alberola Candel V, Calabresi F, Michel RT, Santos R, Delozier T, Goss P, Mauriac L, Feuilhade F, Freue M: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol. 1994, Suppl 7: 19-24.
4.
Thurlimann B, Beretta K, Bacchi M: First-line fadrozole HCI (CGS-16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol. 1996, 7: 471-479.CrossRefPubMed
5.
Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomised, cross-over study. J Clin Oncol. 2002, 20: 751-757. 10.1200/JCO.20.3.751.CrossRefPubMed
6.
Gershanovich M, Chaudri HA, Campos D: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Control Group (AR/BC3). Ann Oncol. 1998, 9: 639-645. 10.1023/A:1008226721932.CrossRefPubMed
7.
Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, et al: An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer. 2003, 39: 2318-2327. 10.1016/S0959-8049(03)00630-0.CrossRefPubMed
8.
Cole MP, Jones CTA, Todd IDH: A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI 146474. Br J Cancer. 1971, 25: 270-275.CrossRefPubMedPubMedCentral
9.
Mouridson H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleebom HP, Joenicke F, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003, 21: 2101-2109. 10.1200/JCO.2003.04.194.CrossRef
10.
Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, et al: Mature results of a randomised phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003, 14: 1391-1398. 10.1093/annonc/mdg362.CrossRefPubMed
11.
Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, Casanovas J, Puig-Gali M: Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer. Am J Clin Oncol. 2003, 26: 317-322. 10.1097/00000421-200306000-00022.PubMed
12.
Nabholtz JM, Buzdar A, Pollak M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000, 18: 3758-3776.PubMed
13.
Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomised double-blind multicenter study. Ann Oncol. 2001, 132: 1527-1532. 10.1023/A:1013128213451.CrossRef
14.
Baum M, Cuzick J, Forbes J, Houghton J, Howell A, (The ATAC Trialists Group): Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003, 98: 1802-1810. 10.1002/cncr.11745.CrossRefPubMed
15.
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massobrio M, Benedetto C, Porpiglia M, Rinaldini M, Paladini G, Distante V, et al: Anastrozole appears to be superior to tamoxifen in women already receiving tamoxifen treatment [abstract]. Breast Cancer Res Treat. 2003, Suppl 1: S6-
16.
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004, 350: 1081-1092. 10.1056/NEJMoa040331.CrossRefPubMed
17.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Mansi J, Castiglioni M, Dongsheng T, Shepherd L, et al: A randomized double-blind clinical trial evaluating Letrozole adjuvant therapy in postmenopausal women with early stage breast cancer completing five years of tamoxifen. N Engl J Med. 2003, 349: 1793-1802. 10.1056/NEJMoa032312.CrossRefPubMed
18.
Ellis MJ, Coop A, Singh B, Mauriac L, Llambert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001, 19: 3808-3816.PubMed
19.
Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, vonEuler M: Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol. 2000, 18: 3748-3757.PubMed
20.
Dixon JM, Love CDB, Renshaw L, Bellamy C, Cameron DA, Miller WR, Leonard RCF: Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer. 1999, 6: 227-230. 10.1677/erc.0.0060227.CrossRefPubMed
21.
Long BJ, Jelovac D, Thiantanawat A, Brodie AM: The effect of second line antiestrogen therapy on breast tumour growth after first line treatment with the aromatase inhibitor letrozole: long term studies using the intratumoural aromatase post menopausal breast cancer model. Clin Cancer Res. 2002, 8: 2738-2388.
22.
Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM: Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst. 2004, 96: 465-465.CrossRef
23.
Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signalling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003, 9: 447S-454S.PubMed
24.
Nemere I, Pietras RJ, Blackmore PF: Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem. 2003, 88: 438-445. 10.1002/jcb.10409.CrossRefPubMed
25.
Kurokawa H, Arteaga CL: ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res. 2003, 9: 511S-515S.PubMed
26.
Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003, 95: 353-361. 10.1093/jnci/95.5.353.CrossRefPubMed
27.
Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bieche I: Expression analysis of estrogen receptor coregulators in breast carcinoma: evidence that NCOR1 expression is predictive for the response to tamoxifen. Clin Cancer Res. 2003, 9: 1259-1266.PubMed
28.
Howell A, Dodwell D, Anderson H, Redford J: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol. 1992, 3: 611-617.PubMed
29.
Osborne KO, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of breast cancer. J Natl Cancer Inst. 1995, 87: 746-750.CrossRefPubMed
30.
Gottardis MM, Jiang MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989, 49: 4090-4093.PubMed
31.
DeFriend D, Anderson E, Bell J, Wilks DP, West CML, Mansel RE, Howell A: Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer. 1995, 70: 204-221.CrossRef
32.
Ellis MJ, Coop A, Singh B, Tao Y, Liombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003, 63: 6523-6231.PubMed
33.
Masamura S, Santner SJ, Heitjan DF, Santen RJ: Estrogen deprivation causes estrogen hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995, 80: 2918-2925. 10.1210/jc.80.10.2918.PubMed
34.
Martin LA, Farmer I, Johnston SRD, Ali S, Marshall C, Dowsett M: Enhanced estrogen receptor (ER)α ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003, 278: 30458-30468. 10.1074/jbc.M305226200.CrossRefPubMed
35.
Bernstein LM, Zheng H, Yue W, Wang J-P, Lykkes feldt AE, Naftolin F, Harada N, Shanabrough M, Santen RJ: New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer. 2003, 10: 267-277. 10.1677/erc.0.0100267.CrossRef
36.
Santen RJ, Song RX, Zhang Z, Kumar R, Jeng M-H, Masamura S, Yue W, Berstein L: Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer. 2003, 10: 111-130. 10.1677/erc.0.0100111.CrossRefPubMed
37.
Allred DC, Harvey JM, Berardo M: Prognosis and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMed
38.
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, et al: Quantitative association between HER/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003, 95: 142-153. 10.1093/jnci/95.2.142.CrossRefPubMed
39.
Dowsett M, on behalf of the ATAC Trialists Group: Analysis of time to recurrence in the ATAC trial according to estrogen receptor and progesterone receptor status [abstract]. Breast Cancer Res Treat. 2003, Suppl 1: S27-
40.
Ellis M: Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist. 2004, Suppl 3: 20-26. 10.1634/theoncologist.9-suppl_3-20.CrossRef
Metadaten
Titel
Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
verfasst von
Anthony Howell
Mitch Dowsett
Publikationsdatum
01.12.2004
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 6/2004
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr945

Weitere Artikel der Ausgabe 6/2004

Breast Cancer Research 6/2004 Zur Ausgabe

Book report

Bland K, Copeland E: The Breast, 3rd edition. London, Saunders; 2003. 1628 pp.

Research article

Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study

Article selection

Articles selected in September 2004

Review

Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview

Commentary

An early peak of relapse after surgery for breast cancer

Research article

Proteotypic classification of spontaneous and transgenic mammary neoplasms

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise